GLUT3 is highly expressed in brain tumor cells [46], and long-term treatment with temozolomide in human astrocytes resulted in increased expression of GLUT3, indicating that GLUT3 has acquired resistance to the temozolomide drug [47]. Here, SLC2A3 is linked to brain neoplasm.